Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients.
COVID-19
Ct value
Days of symptoms
Mortality
Viral load
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
03
09
2021
accepted:
11
04
2022
pubmed:
14
5
2022
medline:
4
10
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Assess the impact of viral load estimated by cycle threshold (Ct) of reverse transcription real time-polymerase chain reaction (rRT-PCR) and the days from symptoms onset on mortality in hospitalized patients with COVID19. Retrospective observational study of 782 patients with a positive rRT-PCR from a nasopharyngeal swab was performed within the first 24 h from admission. Demographic data, clinical manifestations and laboratory parameters were collected. Uni- and multivariate analyses were performed to identify factors associated with mortality at 60 days. Ct was divided into three groups and the mortality rate decreased from 27.3 to 20.7% and 9.8% for Ct values of ≤ 20, 21-25 and > 25, respectively (P = 0.0001). The multivariate analysis identified as predictors of mortality, a Ct value < 20 (OR 3.13, CI 95% 1.38-7.10), between 21-25 (OR 2.47, CI 95% 1.32-4.64) with respect to a Ct value > 25. Days from symptoms onset is a variable associated with mortality as well (DSOA) ≤ 6 (OR 1.86, CI 95% 1.00-3.46), among other factors. Patients requiring hospital admission within 6 DSOA with a Ct value ≤ 25 had the highest mortality rate (28%). The inclusion of Ct values and DSOA in the characterization of study populations could be a useful tool to evaluate the efficacy of antivirals.
Identifiants
pubmed: 35562568
doi: 10.1007/s15010-022-01833-8
pii: 10.1007/s15010-022-01833-8
pmc: PMC9105593
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1321-1328Investigateurs
J L Blanco
(JL)
J Mallolas
(J)
E Martínez
(E)
M Martínez
(M)
J M Miró
(JM)
A Moreno
(A)
A Del Rio
(A)
M Solá
(M)
M Torres
(M)
A Ugarte
(A)
A Cozar-Lladó
(A)
L Linares
(L)
A Tellez
(A)
S Fernandez
(S)
J M Nicolas
(JM)
D Campubri
(D)
M T de Alba
(MT)
M Fernandez
(M)
E Ferrer
(E)
B Grau
(B)
H Marti
(H)
M Muelas
(M)
M J Pinazo
(MJ)
N Rodriguez
(N)
M Roldan
(M)
C Subira
(C)
I Vera
(I)
N Williams
(N)
A Almuedo-Riera
(A)
A Aldea
(A)
M Camafort
(M)
J Calvo
(J)
A Capdevila
(A)
F Cardellach
(F)
I Carbonell
(I)
E Coloma
(E)
A Foncillas
(A)
R Estruch
(R)
M Feliu
(M)
J Fernández-Solá
(J)
I Fuertes
(I)
C Gabara
(C)
I Grafia
(I)
A Ladino
(A)
R López-Alfaro
(R)
A López-Soto
(A)
F Masanés
(F)
A Matas
(A)
M Navarro
(M)
J Marco-Hernández
(J)
L Miguel
(L)
J C Milisenda
(JC)
P Moreno
(P)
J Naval
(J)
D Nicolás
(D)
H Oberoi
(H)
J Padrosa
(J)
S Prieto-González
(S)
M Pellicé
(M)
J Ribot
(J)
O Rodríguez-Núnez
(O)
E Sacanella
(E)
F Seguí
(F)
C Sierra
(C)
A Tomé
(A)
M Torres
(M)
H Ventosa
(H)
C Zamora-Martínez
(C)
M Almela
(M)
M Alvarez
(M)
J Bosch
(J)
J Costa
(J)
G Cuesta
(G)
B Fidalgo
(B)
J Gonzàlez
(J)
F Marco
(F)
S Narvaez
(S)
C Pitart
(C)
E Rubio
(E)
A Vergara
(A)
M E Valls
(ME)
Y Zboromyrska
(Y)
C Casals
(C)
M Mosquera
(M)
E López
(E)
M Tuset
(M)
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1240–2.
doi: 10.1001/jama.2020.2648
Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763–70.
doi: 10.1016/S0140-6736(20)31189-2
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323:1–8.
doi: 10.1001/jama.2020.6775
Garcia-Vidal C, Moreno-García E, Hernández-Meneses M, et al. Personalized therapy approach for hospitalized patients with COVID-19. Clin Infect Dis. 2020;74:127–32.
doi: 10.1093/cid/ciaa964
Zheng Z, Peng F, Xu B, et al. Risk factors of critical and mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:e16–25.
doi: 10.1016/j.jinf.2020.04.021
Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin Infect Dis. 2020;71(16):2199–206.
doi: 10.1093/cid/ciaa576
Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8: e70.
doi: 10.1016/S2213-2600(20)30354-4
Rao SN, Manissero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020;9:573–86.
doi: 10.1007/s40121-020-00324-3
Magleby R, Westblade LF, Trzebucki A, et al. Impact of severe acute respiratory sindrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clin Infect Dis. 2021;73(11):e4197–205.
doi: 10.1093/cid/ciaa851
Huang J-T, Ran R-X, Lv Z-H, et al. Chronological changes of viral shedding in adult inpatients with COVID-19 in Wuhan. China. Clin Infect Dis. 2020;71(16):2158–66.
doi: 10.1093/cid/ciaa631
Westblade LF, Brar G, Pinheiro LC, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020;38:661-671.e2.
doi: 10.1016/j.ccell.2020.09.007
Faíco-Filho KS, Passarelli VC, Bellei N. Is higher viral load in SARS-CoV-2 associated with death? Am J Trop Med Hyg. 2020;103:2019–21.
doi: 10.4269/ajtmh.20-0954
Prebensen C, Hre PLM, Jonassen C, et al. SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19. CID. 2020.
Garcia-Vidal C, Sanjuan G, Puerta-Alcalde P, Moreno-García E, Soriano A. Artificial intelligence to support clinical decision-making processes. EBioMedicine. 2019;46:27–9.
doi: 10.1016/j.ebiom.2019.07.019
Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. CID. 2020.
Rhee C, Kanjilal S, Baker M, Klompas M. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? CID. 2020;1–8.
van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. Clin Infect Dis. 2020;1–28
Xu D, Zhou F, Sun W, et al. Relationship Between serum SARS-CoV-2 nucleic acid (RNAemia) and organ damage in COVID-19 patients: a cohort study. CID. 2020.
Hagman K, Hedenstierna M, Gille-Johnson P, et al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. CID. 2021;73(9):e2995–3001.
doi: 10.1093/cid/ciaa1285
Veyer D, Kernéis S, Poulet G, et al. Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value. Clin Infect Dis. 2020;73:e2890–7.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383:1813–26.
doi: 10.1056/NEJMoa2007764
Poljak M, Korva M, Gašper NK, et al. Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic. J Clin Microbiol. 2020;58(6):e00599–20.
doi: 10.1128/JCM.00599-20
Rahman H, Carter I, Basile K, et al. Interpret with caution: an evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus. J Clin Virol. 2020;127: 104374.
doi: 10.1016/j.jcv.2020.104374
Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229–37.
doi: 10.1056/NEJMoa2029849
Kim PS, Read SW, Fauci AS. Therapy for early COVID-19. JAMA. 2020;324(21):2149–50.
doi: 10.1001/jama.2020.22813